Astex Pharmaceuticals, Inc. ASTX -0.51% , a pharmaceutical company dedicated to the discovery and development of novel therapeutics, announced the acceptance of four abstracts detailing recent work with Astex Pharmaceuticals compounds. Poster presentations will occur on November 13, 14 and 15, 2011 at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in San Francisco, California.The presentations will review pre-clinical advances with AT13387 (HSP90 inhibitor), PKM2 (Pyruvate Kinase) activators, FGFR (Fibroblast Growth Factor Receptor) inhibitor, and second generation PIM Kinase inhibitors. Select posters will be made available for viewing on the company's website www.astx.com following the public presentation.Sunday, Nov 13, 2011 12:30 -- 2:30 pm PT Abstract & Poster #: A217 The HSP90 inhibitor, AT13387, demonstrates potent anti-tumor activity in both imatinib-sensitive and imatinib-resistant gastrointestinal stromal tumor modelsMonday, Nov 14, 2011 12:30 -- 2:30 pm PT Abstract & Poster #: B143 PKM2 metabolic activator slows lung cancer xenograft growthTuesday, Nov 15, 2011 12:30 -- 2:30 pm PT Abstract & Poster # C12 Identification of predictive and pharmacodynamic biomarkers for an FGFR receptor inhibitorTuesday, Nov 15, 2011 12:30 -- 2:30 pm PT Abstract & Poster # C200 Second generation PIM inhibitors exhibit improved activity in solid tumor models
Subscribe to:
Post Comments (Atom)
Superhit News
-
US health regulator USFDA has issued a warning letter to German drug firm Fresenius Kabi AG for lapses at its drug manufacturing fac... -
Goods and Service Tax (GST) is high on the agenda for the new government and its rollout is a priority. GST will benefit the Indian pharma... -
Rib-X Pharmaceuticals, Inc. announced today the signature of an exclusive worldwide research collaboration agreement and option for license ...
-
Physiomics: Reports difficult trading but highlights growing interest from big pharmaceutical groupsPhysiomics ( LON:PYC ) said that trading conditions were difficult in the six months ended 31 December 2010, but it believes it is in a be...
-
Hindusthan National Glass and Industries Ltd is expected to finalize a strategic overseas acquisition in the pharmaceuticals space in the n...
-
The Minister of State (Health and Family Welfare), Sh Ashwini Kumar Choubey through a written reply in the Lok Sabha informed about th... -
The government is hoping to see the implementation of the track and trace system for domestic and export supply chain in another one y... -
India's Central Drugs Standard Control Organization (CDSCO) has suspended the manufacturing of eye drops at the Chennai-based firm after... -
Diclofenac injection is a painkiller which is manufactured by Themis Medicare Ltd and marketed by Novartis India under the brand name ... -
Amylin Pharmaceuticals, Inc. AMLN +16.15% and Alkermes plc ALKS +4.61% today announced that the U.S. Food and Drug Administration (FDA) has ...
No comments:
Post a Comment